These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20976761)

  • 1. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
    Samson K
    Ann Neurol; 2010 Oct; 68(4):A9-A12. PubMed ID: 20976761
    [No Abstract]   [Full Text] [Related]  

  • 2. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
    Schor NF
    Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecule of the month. Semagacestat.
    Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
    [No Abstract]   [Full Text] [Related]  

  • 4. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
    Cummings J
    Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
    [No Abstract]   [Full Text] [Related]  

  • 5. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
    Trechot P; Schmutz JL
    Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
    [No Abstract]   [Full Text] [Related]  

  • 6. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from a failed γ-secretase Alzheimer trial.
    De Strooper B
    Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
    Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
    Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gamma-secretase inhibitors and modulators].
    Iwai A
    Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():83-7. PubMed ID: 22755160
    [No Abstract]   [Full Text] [Related]  

  • 10. Alzheimer's failure raises questions about disease-modifying strategies.
    Extance A
    Nat Rev Drug Discov; 2010 Oct; 9(10):749-51. PubMed ID: 20885394
    [No Abstract]   [Full Text] [Related]  

  • 11. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.
    Hsu CK; Hsu CC; Lee JY; Kuo YM; Pai MC
    J Am Acad Dermatol; 2013 Feb; 68(2):e46-8. PubMed ID: 23317986
    [No Abstract]   [Full Text] [Related]  

  • 12. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
    Hopkins CR
    ACS Chem Neurosci; 2010 Aug; 1(8):533-4. PubMed ID: 22778845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semagacestat for treatment of Alzheimer's disease.
    Gupta VB; Gupta VK; Martins R
    N Engl J Med; 2013 Oct; 369(17):1660-1. PubMed ID: 24152268
    [No Abstract]   [Full Text] [Related]  

  • 14. Semagacestat for treatment of Alzheimer's disease.
    Pomara N
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152269
    [No Abstract]   [Full Text] [Related]  

  • 15. Semagacestat for treatment of Alzheimer's disease.
    Doody RS; Aisen PS; Iwatsubo T
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152267
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
    Henley DB; May PC; Dean RA; Siemers ER
    Expert Opin Pharmacother; 2009 Jul; 10(10):1657-64. PubMed ID: 19527190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase.
    O'Sullivan Coyne G; Woodring TS; Lee CR; Chen AP; Kong HH
    J Invest Dermatol; 2018 Apr; 138(4):979-981. PubMed ID: 29138057
    [No Abstract]   [Full Text] [Related]  

  • 18. New pathway links γ-secretase to inflammation and memory while sparing notch.
    Gandy S; Wustman B
    Ann Neurol; 2011 Jan; 69(1):5-7. PubMed ID: 21280069
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
    Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eric Karran.
    Karran E; Mullard A
    Nat Rev Drug Discov; 2015 Apr; 14(4):230-1. PubMed ID: 25792262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.